EFFICACY OF CORAXAN AND FINOPTIN IN THE TREATMENT OF ANGINA ON EXERTION
<i>The objective of the study was to compare the antianginal and antiischemic efficacy of Coraxan and Finoptin in patients with exertion stable angina and intolerance and/or contraindications to the use of </i>β-<i>adrenoblockers. Following 3-month therapy, the antianginal effect of Coraxan in a dose of 10-15 mg/day was comparable with that of Finoptin in a dose of 240 mg/day, by significantly improving quality of life indicators. Coraxan produced no negative effect on the basic parameters of 24-hour ECG monitoring.</i>